1. Search results in the navigational tree (All hits)
All the results are highlighted by color in the navigational tree
(at the left-hand side) and remain so until you click on a not highlighted menu item and
thus return to the usual content navigation.
In addition, you can browse through the search results consecutively by pressing the navigational buttons
(
<
1 of
11
>).
Within the text the search result is highlighted by color.
2. Search results by relevance (Top 5)
Following is a list of the 5 most important hits ranked by relevance.
Hint: In the
Help you will find explanations about using search operators in order to conduct an extended search.
In the second quarter of 2013, total revenues of the Merck Serono division increased organically by 1.5% in an increasingly difficult market environment. Including a foreign exchange impact of –3.0%, total revenues decreased by –1.5% to € 1,624 million in comparison with the year-earlier quarter (Q2: 2012: € 1,649 million). Despite moderate organic growth of 2.1%, the division’s reported sales declined slightly by –1.0% overall to € 1,531 million due to currency headwinds of –3.1% (Q2 2012: € 1,546 million). The division’s two top-selling products, the multiple sclerosis treatment Rebif® and the cancer therapy Erbitux®, continued to generate [...]
In the second quarter of 2013, the Merck Millipore division achieved a 2.6% increase in sales to € 666 million (Q2 2012: € 649 million). While organically sales were up by a solid 5.6%, changes in foreign exchange rates (especially the Japanese yen) had a negative impact of –3.7%. In addition, last year’s acquisition of Biochrom AG, Berlin, favorably impacted sales by 0.6%. The division reported positive organic growth across the three business units. Royalty income from pharmaceutical-chemical products from Process Solutions decreased in the second quarter to € 2 million (Q2 2012: € 6 million). The Process Solutions business unit, which markets [...]
In a superb second quarter of 2013, sales by the Performance Materials division increased by 1.2% to € 431 million (Q2 2012: € 426 million). While sales grew organically by 5.4%, changes in foreign exchange rates lowered top-line growth by –4.3%. Currency headwinds stemmed mainly from the Japanese yen. Higher sales volumes of liquid crystal materials from the Liquid Crystals business unit, which accounts for more than 70% of Performance Materials sales, fueled organic growth. In particular, demand for materials based on polymer-stabilized vertical alignment (PS-VA) technology, which are primarily used in large-sized, high-quality television displays, was very [...]
In the second quarter of 2013, the Consumer Health division reported sales of € 116 million, a decline of –4.5% compared with the strong year-earlier period (Q2 2012: € 121 million). This reflects an organic sales decrease of –1.0% as well as a negative foreign exchange impact of –3.5%. The organic decline was mainly due to lower sales in Europe, the division’s largest market. Good sales growth in Germany was countered by the discontinuation of export products sold by the British subsidiary Seven Seas which contributed to higher comparable sales last year. The demand for vitamins and mobility products was good in the second quarter. Strategic brands [...]
Highlights – 2nd Quarter 2013 Organic sales growth of 3.3% despite more difficult markets Positive effects of efficiency program “Fit for 2018” well on track Margin expansion in nearly all divisions Increase in EBITDA pre one-time items of 10.7% to € 826 million EPS pre one-time items lifted by 17.7% to € 2.26 Continuous net financial debt reduction to € 1.3 billion at the end of the quarter Guidance for 2013 confirmed despite adverse currency effects: EBITDA pre one-time items ~€ 3.1 to € 3.2 billion XLS Merck Group | Key figures € million Q2 – 2013 Q2 – 2012 Change Jan.–June 2013 Jan.–June 2012 Change Total revenues 2,841.1 2,852.1 [...]
